Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries [Book Review]
Graduate studies at Western
Journal of Business Ethics 84 (1):75 - 88 (2009)
|Abstract||On January 1, 2006, Medicare Part D prescription drug coverage was initiated. Concern was immediately voiced by the American Association of Retired Persons (AARP) and Families USA that, in response to this program, the pharmaceutical industry may raise prices for drugs most often used by the elderly. This article examines the ethical implications of a revenue-maximizing pricing strategy in an industry in which third party financing mitigates an end product's true cost to the user. The perspectives of three stakeholder groups are examined: the elderly, as consumers of prescription drugs, the pharmaceutical industry, as product manufacturer and beneficiary of derived profits, and the total U. S. population, as the ultimate payer for the program via tax revenues. Key questions explored include the relationships among price strategy and access to drugs at both the micro (Medicare cohort) and macro (total population) levels, and on drug development or enhancement. The role of profit in a capitalism-based health care system is also examined. Hospital industry impact on these same stakeholder groups in response to the original 1965 Medicare law is used to compare and contrast possible outcomes of the new drug program. It is predicted that pharmaceutical firms will mimic the hospital industry, adopting a price maximizing strategy for drugs covered by the program. In the process, a utilitarian effect occurs: the benefits of increased access and diffusion of drugs counterbalance inequities in financing Medicare Part D|
|Keywords||access diffusion ethics pricing strategy|
|Categories||categorize this paper)|
|Through your library||Configure|
Similar books and articles
Joao Calinas-Correia (2013). Big Pharma: A Story of Success in a Market Economy. [REVIEW] Medicine, Health Care and Philosophy 16 (2):305-309.
Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1):41-51.
Theodore R. Marmor (1988). Reflections on Medicare. Journal of Medicine and Philosophy 13 (1):5-29.
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Thomas A. Hemphill (2010). Extraordinary Pricing of Orphan Drugs: Is It a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? [REVIEW] Journal of Business Ethics 94 (2):225 - 242.
Added to index2009-01-28
Total downloads13 ( #95,578 of 739,406 )
Recent downloads (6 months)1 ( #61,269 of 739,406 )
How can I increase my downloads?